Concepedia

Author

Paz Ribas

Hospital Universitario Doctor Peset

Also Known As

Concha Poder, P. Melloni Ribas, Patricia Ribas, Paz Ribas

40

Publications

835

Citations

10

H-Index

18

Concepts

All Affiliations

Hospital Universitario Doctor PesetHospital Universitari i Politècnic La FeClinica Universidad de NavarraInstitut Català d'OncologiaResearch Institute Hospital 12 de Octubre
PR

About

Paz Ribas is an author at Hospital Universitario Doctor Peset specializing in hematology, transplantation, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

181

2

Immunology

3

3

181

3

Health Sciences

2

2

105

4

Cellular Therapies

1

1

92

5

Hepatology

1

1

92

Paz Ribas

×

11

Publications

764

Citations

10

H-Index

YearCitations

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández,

Blood

2006

388

Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

Enric Carreras, Laura Rosiñol, María José Terol,

Biology of Blood and Marrow Transplantation

2007

92

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

Margarita Blanes, Juan José Lahuerta, José D. González,

Biology of Blood and Marrow Transplantation

2012

76

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura París,

Blood

2022

67

Quality control of bacterial contamination in autologous peripheral blood stem cells for transplantation.

Luís Larrea, Javier de la Rubia, María Angeles Soler,

PubMed

2004

33

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, María‐Victoria Mateos, Paz Ribas,

Blood

2023

31

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial

Margarita Blanes, Javier de la Rubia, Juan José Lahuerta,

Leukemia & lymphoma/Leukemia and lymphoma

2009

30

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY

Sandy W. Wong, Noffar Bar, María‐Victoria Mateos,

HemaSphere

2023

14

Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?

Javier de la Rubia, María José Cejalvo, Paz Ribas

Leukemia & lymphoma/Leukemia and lymphoma

2015

13

Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

Margarita Blanes, José D. González, Juan José Lahuerta,

Leukemia & lymphoma/Leukemia and lymphoma

2014

10

Page 1